- Home
- EBS vs QURE Comparison
EBS vs QURE Comparison
Compare EBS & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- QURE
- Stock Information
- Founded
- EBS 1998
- QURE 1998
- Country
- EBS United States
- QURE Netherlands
- Employees
- EBS N/A
- QURE N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- QURE Health Care
- Exchange
- EBS Nasdaq
- QURE Nasdaq
- Market Cap
- EBS 459.6M
- QURE 432.6M
- IPO Year
- EBS 2006
- QURE 2007
- Fundamental
- Price
- EBS $11.98
- QURE $7.64
- Analyst Decision
- EBS Buy
- QURE Buy
- Analyst Count
- EBS 3
- QURE 6
- Target Price
- EBS $14.00
- QURE $17.00
- AVG Volume (30 Days)
- EBS 1.3M
- QURE 699.6K
- Earning Date
- EBS 11-06-2024
- QURE 11-05-2024
- Dividend Yield
- EBS N/A
- QURE N/A
- EPS Growth
- EBS N/A
- QURE N/A
- EPS
- EBS N/A
- QURE N/A
- Revenue
- EBS $1,125,500,000.00
- QURE $28,587,000.00
- Revenue This Year
- EBS $6.83
- QURE $178.43
- Revenue Next Year
- EBS $2.50
- QURE $49.15
- P/E Ratio
- EBS N/A
- QURE N/A
- Revenue Growth
- EBS 2.05
- QURE N/A
- 52 Week Low
- EBS $1.42
- QURE $3.73
- 52 Week High
- EBS $15.10
- QURE $11.35
- Technical
- Relative Strength Index (RSI)
- EBS 66.68
- QURE 64.80
- Support Level
- EBS $8.66
- QURE $5.35
- Resistance Level
- EBS $12.73
- QURE $7.63
- Average True Range (ATR)
- EBS 0.72
- QURE 0.50
- MACD
- EBS 0.13
- QURE 0.10
- Stochastic Oscillator
- EBS 60.19
- QURE 88.16
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.